Dr. Gregory J. Gerstner, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Southern Illinois University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,262
Licensed in Illinois since 2008, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Southern Illinois University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036.120707 (first issued 2008; active) · AZ license PG PERMIT# 80968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Medical Center Peoria, IL
- Osf Saint Elizabeth MDl Ctr Peru, IL
- Carle Health Methodist Hospital Peoria, IL
- Osf Saint Clare Medical Center Princeton, IL
- Osf Saint PAul Medical Center Mendota, IL
Medical groups
- Oncology-Hematology Associates of Central Illinois P C (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,262
- Services billed
- 356,327
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 44,880 | 68 |
| Injection, ferric carboxymaltose, 1 mg | 24,750 | 25 |
| Injection, pembrolizumab, 1 mg | 18,600 | 26 |
| Injection, azacitidine, 1 mg | 16,500 | 16 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15,630 | 13 |
| Injection, paclitaxel, 1 mg | 14,649 | 28 |
| Injection, oxaliplatin, 0.5 mg | 9,900 | 11 |
| Injection, aprepitant, 1 mg | 9,750 | 33 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,565 | 79 |
| Injection, fosaprepitant, 1 mg | 6,900 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Peoria, IL | 226 |
| Levothyroxine Sodium Other prescribers in Peoria, IL | 211 |
| Dexamethasone Other prescribers in Peoria, IL | 208 |
| Prochlorperazine Maleate Other prescribers in Peoria, IL | 146 |
| Hydroxyurea Other prescribers in Peoria, IL | 139 |
| Prednisone Other prescribers in Peoria, IL | 132 |
| Ondansetron Hcl Other prescribers in Peoria, IL | 123 |
| Eliquis (apixaban) Other prescribers in Peoria, IL | 121 |
| Lenalidomide | 110 |
| Potassium Chloride Other prescribers in Peoria, IL | 105 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $30.65 in total to this clinician.
| Pfizer Inc. | $30.65 |
|---|
| Education | $30.65 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 6, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $86,890 in research payments for these studies, mostly to the institutions running them.
- 1LM SCLC Tecentriq Lurbinectedin
Genentech, Inc. - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC
Genentech, Inc. - PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC
Genentech, Inc. - Neoadjuvant NSCLC
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.